Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
    1.
    发明授权
    Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders 有权
    中性内肽酶(NEP)和人类可溶性内肽酶(hSEP)抑制剂用于预防和治疗神经退行性疾病

    公开(公告)号:US07232813B2

    公开(公告)日:2007-06-19

    申请号:US11030043

    申请日:2005-01-07

    IPC分类号: A61P25/00

    摘要: The invention relates to a novel use of known benzazepine, benzoxazepine, benzo-thiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of neurodegenerative disorders.The compounds of the invention are known from the European patents EP 0 733 642 and EP 0 916 679, and can be described by the general formulae (1): wherein the symbols have the meanings as given above in the description.

    摘要翻译: 本发明涉及已知的苯并氮杂,苯并氧氮杂,苯并硫氮杂-N-乙酸和具有中性肽链内切酶(NEP)和(或)可溶性内肽酶(hSEP)抑制活性的膦酰取代苯并氮杂酮衍生物的新用途。 本发明的化合物可用于制备用于预防和治疗神经变性疾病的药物组合物。 本发明的化合物可以从欧洲专利EP 0 733 642和EP 0 916 679中得知,并且可以由通式(1)描述:其中符号具有上面在说明书中给出的含义。